SELLAS Life Sciences Group, Inc. SLS Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Syndax PharmaceuticalsSNDX

——

IncyteINCY

——

ModernaMRNA

——

Kymera TherapeuticsKYMR

——

Other financials

Income statement

See full

Revenue-—

Gross profit-—

Operating income-$9.3M-52.6%

Net income-$8.4M-44.6%

EPS (diluted)-$0.05+28.6%

Balance sheet

See full

Cash & equivalents$107.1M+277%

Total debt$871.0K+0.1%

Total equity$107.4M+287%

Total assets$114.2M+227%

Cash flow

See full

Operating cash flow-$8.8M+2.5%

Valuation

See full

Market cap$1.8B+674%

Enterprise value$1.7B+826%

Profitability

See full

Gross margin90%-7.4pp

Operating margin-4,195%-4,591pp

Net margin-4,130.1%-4,444pp

FCF margin-300.5%—

Returns & leverage

See full

Return on equity-43.6%-17.9pp

Debt / equity0×0.0×

Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans?: SELLAS Life Sciences Group, Inc. (SLS) reported proceeds from issuance of common stock relating to employee stock plans of $66K in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: SELLAS Life Sciences Group, Inc.'s proceeds from issuance of common stock relating to employee stock plans increased by 37.5% year-over-year, from $48K to $66K.